Drugs / CKD-314
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT04871646 | Jun 2021 → Mar 2022 | pneumonia | Chong Kun Dang Pharmaceutical | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CKD-314 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04871646 ↗ |
| Route | Intravenous | “CKD-314 is administered intravenously” NCT04871646 ↗ |